On U.S. November. today. I update our progress on commercial our for focus call, since in in Thank you, the will primarily joining last today's everyone, call
engaging in communities and teams. medical both with oncologist commercial intervention We interest be the by encouraged to our continue radiology medical
metastatic motivation The which into incorporate is leading working commitment with currently in have HEPZATO melanoma. uveal U.S., and patients across XX interest treating indicated stated company KIT. KIT HEPZATO the centers over Their to cancer their practices with
our third as to I result treating the quarter, the sites the will over of XX guidance regarding which details a by the active of share X increasing of our activation months, achievements we The last active sites of activation team's end from the end sites the active by more end pacing XXXX site of XX are shortly year-end. sites site by second year. will by XX be quarter the and of the by approximate end XX XX
this that our Thomas X adequate our are Moffitt the financial In Moffitt the senior was that Jefferson treated include by Stanford first patients. most University, and Cancer is to announced University quarter, resources, of end By Delcath are the sites. currently $X we Center. important million are financing commercial These It to we current and Center, Cancer Importantly, have January note treating expect achieve and to Cancer patient entirely XXXX, recent supported trained Center which fully commercial at active financing board executives, subsequent investors. members goals. institutional these believe to existing we first
treatments of for end In the quarter, first generated of the of the sites start to first for use temporary patient be sampling of cases first those proctor given week. to University initial at commercial predominantly addition product some X, treat the quarter those and scheduled of is mark In Moffitt. Wisconsin revenue the by the most this the will by
first consistently quarter. second X activated in the generate quarter revenue sites the of the starting balance in to the With
from increase X.X past of to we expect of more quarter, early sites approximately some average, approximately run second be per a per than X others, then critical the and for active ramping While we rate to have per steadily and These in midyear average been treatments on month launched months reaching subsequently the by rate a an run in as X will period KIT per site month the month treatments of company treatments a in the U.S. prepared quarter. fourth X for HEPZATO late
HEPZATO pass-through launch process These teams and affairs suffering early to radiologists, and medical metastatic patients X educate, included provide oncologists and reimbursement objectives. an obtaining code prelaunch medical CMS. broader the commercial a effectively and a benefits commercial of communicating sites. critical to and the accomplish that and During train can efficient to developing period, to status intervention set needed from from product-specific uveal potential activate the melanoma
that demonstrates all to our January achieved product-specific a of launch-related JXXXX X reimbursement transitional is goals. date was HEPZATO, permanent status, April these with believe and will become Supplementing that which I Starting be XXXX. on XX X, XX, March established and for on progress pass-through we which also effective on will CMS on effective product-specific granted X. the what J-code, payment J-code April
reimbursed of hospital While and reimbursement. cannot a HEPZATO unique be risk The C using greatly reimbursement the J-Code aware the of miscellaneous adequate the having the hospitals we simplify a that impact J-Code not code, are and establishment lowered overstated. will the of receiving permanent process for have for successfully been importance a treatment perceived
same U.S. institutions preceptorships, representing care XX intervention XX or providers KIT each working in identify for oncologists sites to In conjunction been anesthesiologists, and with over of date, specialty. multiple with perfusionists, medical target X interventional institutions HEPZATO have radiologists we train have we the radiologists had teams. our To health attend the the and sending with some sites, treatment more approximately at
interest This volume of care incorporate and HEPZATO patients uveal the for a metastatic suffering clear training of U.S. activity the standard success evidence of in the as outreach physician is resulting broad melanoma. from our to of
analysis are KIT also to these working committee have found at to we site shepherd site, training processes. obtain champions MD approvals help to and HEPZATO each additional hospitals, value we addition formulary to the at at HEPZATO each In and treatment continue teams through hospital
reviews specific a greatly product conducting and required after becomes increase simplify we commercial the these on X will the to their fully effective facilities completing significant of J-Code training. first REMS Since pace in treatment see the expect it
fact, just in the first In scheduled X April, of sites weeks have additional treatments. X
obtained. the State Clinic the include Ohio and to commercial hospital have further Memphis analysis and X steps guidance Duke University their proctor first University Health. is necessary University committee Jacksonville treatment These sites formulary once Wexner value of A Tennessee Center, under Medical completed a conduct Mayo of UCLA and approval
are scheduled Committee accepting patient of of hospital formulary commercial April, the quarter, of a X the sites and X weeks before which analysis. currently X referrals, pending which will or which first case have there have of and In another first patient in X total, a Value are conduct end the X sites
sites, beyond -- another XX these sites currently through or X these preceptorship scheduled training. Before approximately to preceptorships have partway XX the are
health committees. to site, which the didactic train experienced traveling a need professionals reviews The by reminder, a to X take proctor to course, approximately first training, analysis formulary of attend months. and And value activation to preceptorship a and a X we hospitals site includes their initially case. center, X can scheduling preceptorship subsequently entire new process from the professionals As activate care to care traveling health to
incorporate metastatic care to the to KIT significant fully the certified and as these HEPZATO level REMS of believe from the providers commitment to all health program, Given providers become uveal cancer all trained intend care for of health approximately their date involved regime the patients. required core part XX we under treatment a melanoma and centers
launching over therapies of achievements Manager members launch Kevin year. has our affairs of the HEPZATO that experience focused point not the of team Interventional bringing team Oncology Muir, a These to been that multiple on a support and hospital building with General for have without setting. medical groups. commercial world-class in operations in Kevin Delcath's well has made would right require impossible a complex stakeholders organization commercial on from
and be into trained KIT commercial is reminder, a for and divided and preparation the networks a and ensure oncologists specialists, the to therapy the treatment that clinical initially manage U.S. team treating will who team teams As within and the treatment of improving who of manager, manager, X HEPZATO a process have by of served oncology the liver-directed which centers the hospital referral the X comprised in supported, patient each the procedure during will regions, outcomes. is goal the we safety building approval who and ensuring with will support of patient
managers to we amount, force increasing and in team this per July. finish by we example, region. may about to moment, the modest time, At of recruiting XX% expect number the oncology of for by increase the field have Over a X place
external procedure, whether activity, efforts option PHX to both melanoma. melphalan addition continue the to is commercial HEPZATO that treatment for an support and to In to dominant add body KIT growing with we CHEMOSAT the patients significant Delcath's important uveal of internal by liver or evidence the delivered utilizing
has the investigator-initiated CHOPIN expect adding reminder, enrolled liver of effect be trial the trial the XX trial plant, the ongoing is of directed evaluating there investigators year. As enrolled to fully of approximately The Europe, end an a II by the patients Phase randomized and this therapy. XX the immunotherapy in chemostat trial to
combination at of X the year the with immunotherapy ipilimumab with trial with of to and primary the of progression-free patients CHEMOSAT objective The patients compare with alone. CHEMOSAT is treated nivolumab treated survival to
trial, control the data an release. do is we investigator-initiated CHOPIN not of As timing
conference second quarter will the However, be our results, that endpoint the is understanding a the oncology including of in primary at presented XXXX. major study
cancers studies, of a radiation In publication announced Research. selective impact of the on the independent metastatic in first life of with SIRT which focused journal Journal and patients of which melanoma and was us the the the help X internal CHEMOSAT results study in investigator-led uveal comparative of fourth of published CHEMOSAT retrospective was second, quarter, on or from Melanoma of the we quality the the and
by SIRT The of over CHEMOSAT X to including in this investigators SIRT comparative with Germany SIRT, conducted advantages clinically the paper, OS. clear CHEMOSAT, CHEMOSAT demonstrated Hospital PHP and in significant multiple and improvement begin treatments from cared cycles are of and University study of statistically versus was meaningful there a
Hampton, U.K. of entitled quality the independent quality of hepatic after University uveal melanoma. of uveal and perfusion impact with reported Hospital of from with publication life South Melphalan conducted on melanoma patients CHEMOSAT was the by life for metastatic PHP investigators second The
of high-dose The by Delcath's utilizing a quality administer delivery concluded CHEMOSAT tolerated well that does their not is life. office and to affect negatively melanoma patients
metastatic tumors, used market treat intrahepatic to potential as to other cancer represents a sizable we is HEPZATO such to treat breast opportunity on, in has uveal cancers metastatic validated metastatic and capitalize for liver, the HEPZATO us believe colorectal cancer, While metastatic neuroendocrine and cholangiocarcinoma. melanoma that the
we operations. increase revenue of plan cash on are similar begin KIT a for future to study treat HEPZATO growth year, while to still We represent in platform. on states growth flows a significant from unmet and And that X within physicians these need that disease believe of medical those in our areas opportunities our focused
the to last CMS year, the major in given train of company risk our XX point and activate J-Code from interest return, summary, inflection product-specific the institutions FDA's sites. proven a approval issuance potential major by ability terms a has KIT In and of of the passed and demonstrated over relative HEPZATO
tremendous suffering of brighter. to treatment Clearly, the now hand patients to we unmet share are to pursue future Delcath position. significant growth over will will details patients Sandra? our While on financial Sandra melanoma foreseeable future, indications for never of the need liver. the some of call for been has cancers additional the from I planning support metastatic given the uveal
